Day Two
Friday July 17, 2025
8:00 am Registration & Coffee
8:50 am Chair’s Opening Remarks
Understanding Perspectives on Pharmacists for Optimizing Patient Access to Obesity & Cardiometabolic Drugs Through Cost Effective & Evidence-Based Formulary Management
9:00 am Current Clinical Management Strategy to Improve Outcomes for GLP-1 Patients
Synopsis
- Discussing current best practices for identifying appropriate patient selection for GLP-1 therapies such as diagnostic criteria, risk stratification and dosage
- Exploring strategies for ongoing patient support and monitoring such as diet, nutrition, and digital health support to enhance long-term adherence and persistence
- Highlighting the importance of combining GLP-1 therapy with lifestyle modifications and collaborative care to achieve comprehensice cardiometabolic risk reduction
9:30 am Understanding the Advantages & Disadvantages of Using Real World Data for the Assessment of Adherence & Persistence with Obesity Medications to Predict Payer Pushback
Synopsis
- Discussing the best sources of RWE and HEOR to improve validity and reliability of studies
- Exploring the advantages of large sample sizes, longitudinal patient journeys and diverse population to gain the most accurate understanding of patient adherence and persistence with obesity medications outside of controlled clinical trial settings
- Uncover the limitations and potential biases associated with real-world data and the difficulty in isolating situational variabilities in real-world settings
10:00 am Real-World Evidence of the Effect of GLP-1 Receptor Agonist Treatment on the Adherence and Persistence of Second-Generation Antipsychotics Using Administrative Claims Data
Synopsis
- Discussing findings from administrative claims data analysis exploring the correlation between the initiation or continuation of GLP-1s and the subsequent adherence and persistence rates of second-generation antipsychotics in relevant patient populations
- Highlighting specific patient characteristic within claims data that demonstrate the effects of SGAs on GLP-1 adherence
- Exploring potential underlying mechanisms that might explain the observed real-world relationship and discussing the implications for clinical practice and treatment strategies for patients on both GLP-1s and SGA
10:30 am Morning Break & Networking
A 5 Year Plan: Understanding the Upcoming Changes in the Anti-Obesity Pharmaceutical Landscape to Make Informed Decisions Around Pricing Negotiations & Payment Plans
11:00 am Focussed Strategy Discussions – An opportunity to unite with the executives working in specific disease areas to brainstorm effective market access strategies and take actionable insights to tackle disease specific challenges
Synopsis
- Diabetes & Weight Management
- MASH & Liver Disease
- CKD & Renal Disease
11:30 am Explaining Inflation Reduction Act Generally, the Negotiation Process, and Potential Interactions with Obesity & CVRM Therapeutics
Synopsis
- Outlining the key provisions of the Inflation Reduction Act guidelines related to drug pricing negotiations
- Emphasizing the impact on existing and future drugs to gain a comprehensive understanding of how this can affect pharmaceutical manufacturers with obesity & CVRM portfolio assets as well as other innovative products
12:00 pm Panel Discussion: Examining the Potential for the Treat and Reduce Obesity Act to be Passed and the Implications of this Act on Market Access
Synopsis
- Analysing the potential impact of TROA on market access for AOMs and how expanded Medicare coverage could influence private payer behaviour
- Discussing the challenges of estimating the budgetary impact of the TROA, considering utilization rates, drug pricing and long-term cost savings associated with obesity reduction
- Understanding how the TROA could impact the pharmaceutical industry’s investment and development of new AOMs to double down on portfolio strategy and potential future pricing agreements
12:30 pm Lunch & Networking
1:30 pm Roundtable Discussions: Discussing the Best Approaches to Future Challenges in Change in Legislation Around Anti-Obesity Medications to Effectively Tackle Upcoming Bottlenecks
Synopsis
- Access Dynamics & Provider Perspective
- Clinical Impact & Patient Experience
- Future Innovation & Investment
2:00 pm Deep Diving into the Cost Effectiveness of Anti-Obesity and Type 2 Diabetes Therapeutics to Encourage Wider Coverage
Synopsis
- Debunking the big price tags carried by AOMs and by highlighting the discrepancy between initial estimates and actual costs
- Understanding the role of pharmaceutical company sponsorships and pharmacy benefit manager discounts in mitigating costs and making AOMs a realistic price for patients
- Emphasizing the importance of accurate cost modelling and population analysis to understand the true effects that providing AOM coverage will have on budgets
Streamlining Market Access Strategies Early in Development to Positively Influence Commercial Strategy & Engage Potential Investors & Partners
2:30 pm Roundtable Discussions: Adapting Payment Models to Incentivize Effective Obesity Management & Reduce Reliance on Patient Out of Pocket Costs
Synopsis
- Value-Based Care and Obesity Management
- Population-Based Payment Models & Community Health
- Addressing Health Equity in Alternative Payment Models
3:00 pm Afternoon Refreshments & Networking
3:30 pm Panel Discussion: Understanding Targeted Coverage for Obesity Drugs by Navigating Comorbidities, Payers & Pharma Acquisitions
Synopsis
- Discussion on the necessity of specific comorbidities such as, prediabetes, osteoarthritis, sleep apnea, heart failure, for obesity drug coverage
- Exploring the challenges payers face in adapting coverage policies for obesity drugs, including rapid policy changes
4:00 pm Evaluating How the Market Access Landscape Can Affect Strategic Development Decisions for Pharma & Biotech Pipeline Management
Synopsis
- Understanding how considering market access strategy early in development can help with fundraising and investor interest
- Considering how manufacturing margins will influence eventual commercial drug pricing and how this will affect reimbursement models
- Comparing the market access challenges for first in class drugs versus modalities that already on the market